Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children
Format: pdf
Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer
Format: pdf
Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®) as a first-line combination treatment for metastatic pancreatic cancer
Format: pdf
Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy
Format: pdf
2019
September 26, 2019 – Cambridge, MA (USA) - Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy
Format: pdf
September 8, 2019 – Cambridge, MA (USA) - Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer
Format: pdf
July 5, 2019 – Cambridge, MA (USA) - Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer
Format: pdf
Jun 24, 2019 – Cambridge, MA (USA) - Ipsen Announces U.S. FDA Approval for Newly Designed Pre-Filled Syringe for Somatuline® Depot (lanreotide)
Format: pdf
Jun 20, 2019 – Cambridge, MA (USA) - Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service
Format: pdf
2018
Oct 21, 2018 – Cambridge, MA (USA) - Ipsen Presents Real-World Pancreatic Cancer Data on ONIVYDE® at the European Society for Medical Oncology (ESMO) 2018 Annual Congress
Format: pdf
Oct 05, 2018 – Cambridge, MA (USA) - Ipsen Presents Data on Somatuline® Depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium
Format: pdf
Oct 03, 2018 – Cambridge, MA (USA) - Ipsen Joins Biotechnology Innovation Organization (BIO) To Advance Growth and Innovation
Format: pdf
Jun 07, 2018 – Boston, MA (USA) - Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts
Format: pdf
Apr 23, 2018 – Basking Ridge, NJ (USA) - Ipsen Announces Efficacy and Safety Data for Dysport® (abobotulinumtoxinA) Across Multiple Therapeutic Uses at the 2018 Annual Meeting of the American Academy of Neurology
Format: pdf
Feb 15, 2018 – Basking Ridge, NJ (USA) - Ipsen Announces Dysport® (abobotulinumtoxinA) Data Presentations Highlighting Duration of Response and Potential Benefit of Repeated Treatment in Spasticity
Format: pdf
Jan 18, 2018 – Basking Ridge, NJ (USA) - Ipsen to Present Data at ASCO GI 2018, Including New Post-Hoc Analyses from ONIVYDE® (irinotecan liposome injection) Phase 3 NAPOLI-1 Trial
Format: pdf
Jan 12, 2018 – Basking Ridge, NJ (USA) - Ipsen appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America
Format: pdf
2017
Oct 12, 2017 – Basking Ridge, NJ (USA) Ipsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
Format: pdf
Oct 11, 2017 – Basking Ridge, NJ (USA) - Ipsen Joins PhRMA to Continue Advancing Research and Innovation
Format: pdf
Oct 04, 2017 – Basking Ridge, NJ (USA) - Ipsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual Meeting
Format: pdf
Sep 18, 2017 – Basking Ridge, NJ (USA) U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Format: pdf
Sep 15, 2017 – Basking Ridge, NJ (USA) - Ipsen Announces Analysis of Managed Medicaid Data of Children with Cerebral Palsy at Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine
Format: pdf
Sep 14, 2017 – Basking Ridge, NJ (USA) - Ipsen Announces Oral and Poster Presentations of abobotulinumtoxinA Data at the 2017 Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine
Format: pdf
Jun 30, 2017 – Basking Ridge, NJ (USA) - Ipsen announces Dysport® (abobotulinumtoxinA) co-promotion agreement with Saol Therapeutics to expand commercial reach in the United States
Format: pdf
Jun 16, 2017 – Basking Ridge, NJ (USA) - Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults
Format: pdf
Apr 19, 2017 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the American Academy of Neurology
Format: pdf
Mar 21, 2017 – Basking Ridge, NJ (USA) - Blazing New Trails™: Updates in the Care of Children with Cerebral Palsy
Format: pdf
Feb 09, 2017 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the Association of Academic Physiatrists
Format: pdf
Jan 18, 2017 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Poster Presentations at ASCO 2017 Gastrointestinal Cancers Symposium
Format: pdf
Jan 09, 2017 – Paris, Fr (France) - Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Format: pdf
2016
Oct 26, 2016 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society
Format: pdf
Oct 19, 2016 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the Annual Meeting of the American Academy of Physical Medicine & Rehabilitation
Format: pdf
Sep 30, 2016 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium
Format: pdf
Sep 21, 2016 – Basking Ridge, NJ (USA) Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine
Format: pdf
Sep 15, 2016 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Eight Presentations for Dysport® (abobotulinumtoxinA) at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine
Format: pdf
Aug 01, 2016 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older
Format: pdf
Jun 04, 2016 – Basking Ridge, NJ (USA) Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome
Format: pdf
Jun 02, 2016 – Basking Ridge, NJ (USA) - Ipsen Announces Data Presentations of Somatuline® Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
Format: pdf
Apr 06, 2016 – Basking Ridge, NJ (USA) Carcinoid Cancer Foundation and Self Care Catalysts Inc. to Provide a Free Digital Patient Support Application for Carcinoid and Neuroendocrine Tumor (NET) Patients, Sponsored in Part by Ipsen Biopharmaceuticals, Inc.
Format: pdf
2015
Oct 22, 2015 – Basking Ridge, NJ (USA) - Presentation of Results at the AACPDM Annual Meeting from a Phase III Trial Evaluating an Investigational Use of AbobotulinumtoxinA (Dysport®) in Children with Spastic Equinus Foot Deformity due to Cerebral Palsy
Format: pdf
Oct 15, 2015 – Basking Ridge, NJ (USA) - Ipsen Announces Eight Studies of Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society (NANETS) Symposium
Format: pdf
Oct 01, 2015 – Basking Ridge, NJ (USA) - Ipsen Announces Release of Additional Batch of Increlex® (mecasermin [rDNA origin] injection) in the U.S.
Format: pdf
Aug 31, 2015 – Basking Ridge, NJ (USA) Ipsen announces The Lancet Neurology publishes Dysport® Phase III registration trial results in adult patients with upper limb spasticity (ULS)
Format: pdf
Aug 04, 2015 – Sacramento, CA (USA) - Ipsen Biopharmaceuticals, Inc. Receives Statewide Award for Achievements in Product Stewardship
Format: pdf
May 14, 2015 – Basking Ridge, NJ (USA) - Ipsen Announces Data Presentations for Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
Format: pdf
Jan 13, 2015 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals To Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium
Format: pdf
2014
Dec 16, 2014 – Basking Ridge, NJ (USA) - Ipsen announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the treatment of gastroenteropancreatic neuroendocrine tumors
Format: pdf
Dec 01, 2014 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients
Format: pdf
Nov 24, 2014 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARES™, An Enhanced Patient Support Program
Format: pdf
Nov 14, 2014 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Presents Dysport® (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly
Format: pdf
Nov 06, 2014 – Basking Ridge, NJ (USA) - Ipsen Announces FDA Approval of a New Delivery Device for Somatuline® Depot® (lanreotide) Injection
Format: pdf
Nov 05, 2014 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Format: pdf
Sep 18, 2014 – Basking Ridge, NJ (USA) - Baseline Data from a Phase III Trial in Pediatric Cerebral Palsy Presented at Meeting of the American Academy for Cerebral Palsy and Developmental Medicine
Format: pdf
Sep 10, 2014 – Basking Ridge, NJ (USA) - Ipsen Biopharmaceuticals, Inc. Announces Key Medical and Commercial Hires
Format: pdf
Sep 01, 2014 – Basking Ridge, NJ (USA) - Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review
Format: pdf
Aug 26, 2014 – Basking Ridge, NJ (USA) - Ipsen Announces Second Resupply of Increlex®(mecasermin [rDNA origin] Injection) in the U.S. in 2014
Format: pdf
Jul 16, 2014 – Basking Ridge, NJ (USA) - New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Format: pdf
Jul 01, 2014 – Basking Ridge, NJ (USA) - Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Format: pdf
May 13, 2014 – Basking Ridge, NJ (USA) - Ipsen announces a step forward in the resupply of Increlex ® (mecasermin [rDNA origin] injection) in the U.S.
Format: pdf
May 06, 2014 – Basking Ridge, NJ (USA) - Ipsen Announces Name Change for its Research and Development Affiliate in the U.S. From Biomeasure to Ipsen Bioscience, Inc.
Format: pdf
Jan 17, 2014 – Paris, Fr (France) - Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint
Format: pdf
Jan 14, 2014 – Paris, Fr (France) - Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors
Format: pdf
2013
Sep 26, 2013 – Paris, Fr (France) - Ipsen to relocate US R&D activities to Cambridge, MA in 2014
Format: pdf
Jul 15, 2013 – Paris, Fr (France) - Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases
You are about to leave Ipsen.com/us. This link is provided as a service to our website visitors. It will take you to a website maintained by a third party who is solely responsible for its content. Ipsen.com/us does not control, recommend, endorse or accept liability for sites controlled by third parties.
You are about to leave Ipsen.com/us. This link is provided as a service to our website visitors. It will take you to another website maintained by Ipsen.com/us.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site, we will assume that you are happy with it. Please read the Privacy Policy for more information.OKPrivacy policy